Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P (2018)
Publication Type: Journal article
Publication year: 2018
Book Volume: 144
Pages Range: 1701-1709
Journal Issue: 9
DOI: 10.1007/s00432-018-2694-5
PURPOSE: The proto-oncogene forkhead box M1 (FOXM1) is associated with poor survival in many cancers. The impact of FOXM1 expression on progression-free survival (PFS) of non-muscle invasive bladder cancer (NMIBC) has not yet been investigated. The differential expression of FOXM1 between the different molecular NMIBC subtypes has further been assessed. METHODS: Transcript levels of FOXM1 and MKI67 were determined in 460 NMIBC patients (UROMOL cohort) by RNA-Seq and validated in silico by the Chungbuk and Lund cohort (n = 277). FOXM1 and MKI67 cutoffs were identified by the minimal p value method. Variables were evaluated by multivariable Cox regression analyses in order to identify independent predictors. RESULTS: FOXM1 is an independent predictor for PFS superior to current histological, clinical and molecular staging methods. Patients with high FOXM1 expression have a 6- to 8-fold higher risk of progression in multivariable analysis (p < 0.03). Highest transcript levels were found in the Class 2 and genomically unstable molecular NMIBC subtype (p < 0.03). The proto-oncogene further positively correlated with tumor grade and stage. NMIBCs with high FOXM1 expression showed a PFS advantage when treated with intravesical BCG instillation. CONCLUSION: FOXM1 is a highly prognostic marker for disease progression of NMIBC superior to current histological, clinical and molecular staging methods and MKI67. It is mainly expressed in the Class 2 and genomically unstable molecular bladder cancer subtypes. Its role in drug resistance development makes FOXM1 valuable biomarker for NMIBC risk stratification.
APA:
Rinaldetti, S., Wirtz, R., Worst, T.S., Hartmann, A., Breyer, J., Dyrskjot, L., & Erben, P. (2018). FOXM1 predicts disease progression in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 144(9), 1701-1709. https://doi.org/10.1007/s00432-018-2694-5
MLA:
Rinaldetti, Sebastien, et al. "FOXM1 predicts disease progression in non-muscle invasive bladder cancer." Journal of Cancer Research and Clinical Oncology 144.9 (2018): 1701-1709.
BibTeX: Download